-

12:25:41 AM

ONCY Stock News

ONCY - Oncolytics Biotech, Inc.

06/05/23 7:00 AM

Nasdaq : ONCY

clinical trial

Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate

Oncolytics Biotech ® Inc. today announced updated results from BRACELET-1, a...

RHEA-AI

neutral

05/26/23 11:30 AM

Nasdaq : ONCY

conferences

Oncolytics Biotech® to Host Key Opinion Leader Webinar on Data from the Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer Being Presented at the Upcoming ASCO Annual Meeting

Oncolytics Biotech ® Inc. announced that it will host a key opinion leader webinar to discuss data from the randomized phase 2 BRACELET-1 trial in HR+/ HER2- metastatic breast cancer, which will be featured in an oral presentation at the...

RHEA-AI

neutral

05/25/23 5:41 PM

Nasdaq : ONCY

clinical trial

Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract

Oncolytics Biotech ® Inc. today announced positive results from BRACELET-1, a randomized phase 2 trial in...

RHEA-AI

neutral

05/10/23 7:00 AM

Nasdaq : ONCY

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Oncolytics Biotech ® Inc., today announced the voting results from its Annual General Meeting of Shareholders held on Tuesday, May 9, 2023. A total of 44% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting. On a vote by ballot, the seven...

RHEA-AI

neutral

05/05/23 7:00 AM

Nasdaq : ONCY

earnings

Oncolytics Biotech® Reports First Quarter 2023 Financial Results and Operational Highlights

Randomized phase 2 data from BRACELET-1 trial in HR+/ HER2- metastatic breast cancer to be shared in an oral presentation at the American Society of Clinical Oncology Annual Meeting. $29.7 million in cash, cash equivalents, and marketable securities as of March 31, 2023 provides projected cash runway for at least 12 months. SAN DIEGO, Calif. and CALGARY, AB, May 5,...

RHEA-AI

neutral

04/26/23 10:44 AM

Nasdaq : ONCY

Oncolytics Biotech® Announces Upcoming Oral Presentation on Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer at the ASCO Annual Meeting

Oncolytics Biotech ® Inc. today announced the acceptance of an abstract for an oral presentation at the American Society of Clinical Oncology Annual Meeting, which is taking place from June 2– 6, 2023 in Chicago, Illinois and online. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech...

RHEA-AI

neutral

04/12/23 7:23 AM

Nasdaq : ONCY

conferences

Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference

Oncolytics Biotech ® Inc. today announced that Chief Medical Officer Thomas Heineman, M.D., Ph.D., will participate in the Viral Immunotherapy– Moving Forward panel at Canaccord Genuity's Horizons in Oncology Virtual Conference, which is taking place virtually on April 20, 2023. Date: Thursday, April 20, 2023...

RHEA-AI

neutral

04/12/23 7:00 AM

Nasdaq : ONCY

conferencesearnings

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will host a conference call and webcast on Friday, May 5, 2023, at 8:30 a.m. ET to

RHEA-AI

neutral

04/12/23 6:45 AM

Nasdaq : ONCY

Oncolytics Biotech® Announces Filing and Mailing of the Management Information Circular in Connection with the Annual General Meeting of Shareholders

Oncolytics Biotech ® Inc. is...

RHEA-AI

neutral

03/28/23 7:00 AM

Nasdaq : ONCY

conferences

Oncolytics Biotech® to Participate in a Panel Presentation at Cantor Fitzgerald's The Future of Oncology Virtual Symposium

Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, President and Chief Executive Officer, will participate in the Novel Mechanisms with Important Readouts panel at Cantor Fitzgerald's The Future of

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next